Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Novavax Beat the Market on Monday

TheMotleyFool

0 0

Novavax (NASDAQ: NVAX), best known these days for the NVX-CoV2373 coronavirus vaccine it's developed, saw its shares rise by 1.5% on Monday, against a stock market that essentially traded sideways. Investors seemed to be cautiously optimistic about the company's latest news on the regulatory front.

Novavax announced that it has formally submitted a biologics license application (BLA) for NVX-CoV2373 to South Korea's Ministry of Food and Drug Safety. It has done so in collaboration with South Korean biotech SK bioscience.

Image source: Getty Images.

Source Fool.com

Like: 0

NVAX

Share